Market Exclusive

AbbVie Inc (NYSE:ABBV) gets upgraded to Outperform by Svb Leerink with a price target of $88.00

Analyst Ratings For AbbVie Inc (NYSE:ABBV)

Today, AbbVie Inc (NYSE:ABBV) stock received an upgrade by Svb Leerink from Market Perform to Outperform with a price target of $88.00.

There are 9 Hold Ratings, 6 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on AbbVie Inc (NYSE:ABBV) is Hold with a consensus target price of $95.4407 per share, a potential 40.87% upside.

Some recent analyst ratings include

About AbbVie Inc (NYSE:ABBV)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Recent Trading Activity for AbbVie Inc (NYSE:ABBV)
Shares of AbbVie Inc closed the previous trading session at 67.86 up +2.16 3.29% with 24569951 shares trading hands.

Exit mobile version